GlycoMimetics Inc. (GLYC) VP Helen M. Thackray Sells 4,000 Shares
GlycoMimetics Inc. (NASDAQ:GLYC) VP Helen M. Thackray sold 4,000 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the sale, the vice president now owns 156,715 shares in the company, valued at approximately $1,097,005. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
GlycoMimetics Inc. (NASDAQ:GLYC) opened at 6.63 on Wednesday. The firm’s market cap is $152.86 million. The stock has a 50 day moving average price of $7.37 and a 200 day moving average price of $7.19. GlycoMimetics Inc. has a one year low of $3.70 and a one year high of $9.25.
Several institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. bought a new position in GlycoMimetics during the second quarter worth about $143,000. BVF Inc. IL bought a new position in GlycoMimetics during the second quarter worth about $17,793,000. Barclays PLC raised its position in GlycoMimetics by 77.1% in the second quarter. Barclays PLC now owns 15,816 shares of the company’s stock worth $115,000 after buying an additional 6,885 shares in the last quarter. State Street Corp bought a new position in GlycoMimetics during the second quarter worth about $751,000. Finally, TFS Capital LLC bought a new position in GlycoMimetics during the second quarter worth about $149,000. 80.28% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have weighed in on GLYC shares. Cowen and Company started coverage on GlycoMimetics in a research note on Monday, August 15th. They set an “outperform” rating on the stock. Stifel Nicolaus boosted their price target on GlycoMimetics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 5th. SunTrust Banks Inc. started coverage on GlycoMimetics in a research note on Tuesday, July 26th. They set a “buy” rating and a $16.00 price target on the stock. Canaccord Genuity reiterated a “buy” rating and set a $12.00 price target on shares of GlycoMimetics in a research note on Sunday, August 7th. Finally, Jefferies Group reiterated a “buy” rating on shares of GlycoMimetics in a research note on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $12.35.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.